DOI: 10.7664/CHE20181007
Evaluation of Targeted Anticancer Agents Incorporated into Medical Insurance Policy: Taking a Tertiary Oncology Institution in Beijing as an Example
Abstract：Objective: To evaluate changes in cost indicators of medical institution before and after the reimbursement policy of targeted drugs incorporated into the medical insurance, and provide data support for the continued advancement of medical insurance payment reform. Methods: Retrospectively by collecting monthly data of hospitalized patients before and after the targeted agents’ reimbursement policy in a cancer hospital of Beijing, and using interrupted time series analysis to explore the immediate effects and long-term trends after the reform. Results: After the reform, the number of daily outpatient visits rose by 20.04 per month; the outpatient and inpatient per capita costs changed by 33.44 yuan and 468.75 yuan respectively, the outpatient and inpatient proportion of drugs increased by 1.80% and 1.89% respectively; the proportion of outpatient auxiliary drug use had a long-term decline trend of 0.61%; the ratio at patients’ own expense fell immediately, and the actual compensation rate increased as well. Conclusion: After the implementation of target agents incorporated into medical insurance reimbursement policy, the individual burden of the patients could be controlled while the rational use of clinical medicine could be improved, however, it would bring the dual control pressure of the fund and the ratio of the medicine, so the top design should be integrated.
Keywords：targeted anticancer agentsmedical insurancemedical institutionpolicy evaluation
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 30-34 )